ORMP Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

-0.040

-118.18%

-0.040

-91.67%

0.000

-100%

Estimates Revision

The market is revising No Change the revenue expectations for Oramed Pharmaceuticals Inc. (ORMP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 46.84%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+46.84%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Oramed Pharmaceuticals Inc (ORMP.O) is 1.05, compared to its 5-year average forward P/E of -10.64. For a more detailed relative valuation and DCF analysis to assess Oramed Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.64

Current PE

1.05

Overvalued PE

-0.36

Undervalued PE

-20.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.39

Current EV/EBITDA

0.95

Overvalued EV/EBITDA

2.30

Undervalued EV/EBITDA

-5.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

81.65

Current PS

0.43

Overvalued PS

151.65

Undervalued PS

11.64

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ORMP News & Events

Events Timeline

No data

News

8.0

01-07Newsfilter

Oramed Pharmaceuticals Receives $18 Million Payment, Declares $0.25 Dividend

8.0

2025-11-17Newsfilter

ORAMED PHARMACEUTICALS INC. ANNOUNCES DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS AS DIVIDEND

9.5

2025-11-17PRnewswire

Oramed Reports Fiscal Third Quarter 2025 Financial Results

People Also Watch

Frequently Asked Questions

What is Oramed Pharmaceuticals Inc (ORMP) stock price today?

The current price of ORMP is 3.48 USD — it has increased 6.42 % in the last trading day.

What is Oramed Pharmaceuticals Inc (ORMP)'s business?

Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

What is the price predicton of ORMP Stock?

Wall Street analysts forecast ORMP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORMP is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Oramed Pharmaceuticals Inc (ORMP)'s revenue for the last quarter?

Oramed Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Oramed Pharmaceuticals Inc (ORMP)'s earnings per share (EPS) for the last quarter?

Oramed Pharmaceuticals Inc. EPS for the last quarter amounts to 1.13 USD, decreased -335.42 % YoY.

What changes have occurred in the market's expectations for Oramed Pharmaceuticals Inc (ORMP)'s fundamentals?

How many employees does Oramed Pharmaceuticals Inc (ORMP). have?

Oramed Pharmaceuticals Inc (ORMP) has 13 emplpoyees as of January 09 2026.

What is Oramed Pharmaceuticals Inc (ORMP) market cap?

Today ORMP has the market capitalization of 138.51M USD.